Rothwell Figg

Several patent litigations have been filed involving mRNA pioneers such as Moderna, Inc. and BioNTech, Inc. (with Pfizer) over the past year relating to sales of the Moderna and BioNTech/Pfizer COVID-19 vaccine products (Spikevax® and Comirnaty®, respectively).  This post provides an overview of those cases, other cases involving other mRNA pioneers, and the overall mRNA

In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022, Arbutus Biopharma Corporation (“Arbutus”) and Genevant Sciences GmbH (“Genevant”) sued Moderna, Inc. and ModernaTX, Inc. (collectively “Moderna”) in the United States District Court for the District of Delaware.

The plaintiffs have alleged that Moderna infringed U.S. Patent Nos. 8,058,069

mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria.  Its efforts are geographically focused on Africa, and the company said it is furthering those efforts to build manufacturing capacity on the African continent.
This all comes on the heels of being the first to ever put an